Penumbra Q3 net income falls 8% to $42.28 million; Q3 revenue rises 16% to $410.15 million

By Public Technologies
  • Penumbra's third-quarter 2026 net income fell 8% year over year to $42.28 million.
  • Revenue rose 16% year over year to $410.15 million.
  • Global thrombectomy revenue climbed 18% year over year to $279.16 million.
  • The company will not provide full-year 2026 guidance given its pending acquisition by Boston Scientific.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291605PR_NEWS_USPR_____SF83735) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk